IS2989B - Pólýalkýlenfjölliðusambönd og gagn af þeim - Google Patents

Pólýalkýlenfjölliðusambönd og gagn af þeim

Info

Publication number
IS2989B
IS2989B IS7353A IS7353A IS2989B IS 2989 B IS2989 B IS 2989B IS 7353 A IS7353 A IS 7353A IS 7353 A IS7353 A IS 7353A IS 2989 B IS2989 B IS 2989B
Authority
IS
Iceland
Prior art keywords
benefits
polymer compounds
polyalkylene polymer
polyalkylene
compounds
Prior art date
Application number
IS7353A
Other languages
English (en)
Icelandic (is)
Other versions
IS7353A (is
Inventor
Lin Kochung
Blake Pepinsky R.
Ling Chen Ling
M. Hess Donna
Y. Lin Edward
C. Petter Russell
P. Baker Darren
Original Assignee
Biogen Idec MA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc. filed Critical Biogen Idec MA Inc.
Publication of IS7353A publication Critical patent/IS7353A/is
Publication of IS2989B publication Critical patent/IS2989B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
IS7353A 2002-01-18 2004-07-15 Pólýalkýlenfjölliðusambönd og gagn af þeim IS2989B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18
PCT/US2003/001559 WO2003061577A2 (en) 2002-01-18 2003-01-17 Polyalkylene glycol with moiety for conjugating biologically active compound

Publications (2)

Publication Number Publication Date
IS7353A IS7353A (is) 2004-07-15
IS2989B true IS2989B (is) 2017-11-15

Family

ID=27613339

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7353A IS2989B (is) 2002-01-18 2004-07-15 Pólýalkýlenfjölliðusambönd og gagn af þeim

Country Status (35)

Country Link
US (2) US8017733B2 (US20030051240A1-20030313-M00001.png)
EP (3) EP3025726B1 (US20030051240A1-20030313-M00001.png)
JP (5) JP2005526151A (US20030051240A1-20030313-M00001.png)
KR (1) KR100964411B1 (US20030051240A1-20030313-M00001.png)
CN (2) CN101700401B (US20030051240A1-20030313-M00001.png)
AU (1) AU2003210564B2 (US20030051240A1-20030313-M00001.png)
BE (1) BE2016C040I2 (US20030051240A1-20030313-M00001.png)
BG (1) BG66525B1 (US20030051240A1-20030313-M00001.png)
BR (1) BRPI0306993B8 (US20030051240A1-20030313-M00001.png)
CA (4) CA2952488C (US20030051240A1-20030313-M00001.png)
CY (2) CY2016027I1 (US20030051240A1-20030313-M00001.png)
CZ (1) CZ2004877A3 (US20030051240A1-20030313-M00001.png)
DK (2) DK1476181T3 (US20030051240A1-20030313-M00001.png)
EA (2) EA011829B1 (US20030051240A1-20030313-M00001.png)
EE (1) EE05509B1 (US20030051240A1-20030313-M00001.png)
ES (2) ES2566797T3 (US20030051240A1-20030313-M00001.png)
GE (2) GEP20074024B (US20030051240A1-20030313-M00001.png)
HK (3) HK1072721A1 (US20030051240A1-20030313-M00001.png)
HU (4) HUE047557T2 (US20030051240A1-20030313-M00001.png)
IL (1) IL163006A (US20030051240A1-20030313-M00001.png)
IS (1) IS2989B (US20030051240A1-20030313-M00001.png)
LU (1) LU93162I2 (US20030051240A1-20030313-M00001.png)
ME (2) MEP35608A (US20030051240A1-20030313-M00001.png)
MX (1) MXPA04006855A (US20030051240A1-20030313-M00001.png)
NL (1) NL300826I2 (US20030051240A1-20030313-M00001.png)
NO (3) NO339857B1 (US20030051240A1-20030313-M00001.png)
NZ (1) NZ534708A (US20030051240A1-20030313-M00001.png)
PL (2) PL397261A1 (US20030051240A1-20030313-M00001.png)
PT (1) PT3025726T (US20030051240A1-20030313-M00001.png)
RS (1) RS55578B1 (US20030051240A1-20030313-M00001.png)
SI (2) SI1476181T1 (US20030051240A1-20030313-M00001.png)
SK (1) SK3102004A3 (US20030051240A1-20030313-M00001.png)
UA (1) UA82184C2 (US20030051240A1-20030313-M00001.png)
WO (1) WO2003061577A2 (US20030051240A1-20030313-M00001.png)
ZA (1) ZA200406555B (US20030051240A1-20030313-M00001.png)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952488C (en) * 2002-01-18 2019-05-07 Biogen Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compounds
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CA2511814C (en) * 2002-12-26 2015-02-17 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
SI1635875T1 (sl) 2003-06-26 2009-04-30 Psivida Inc Sistem za dajanje zdravila, ki se gelira in situ
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
US20090312344A1 (en) * 2004-05-31 2009-12-17 Mohammad Salman Arylpiperazine derivatives as adrenergic receptor antagonists
EP1827501B2 (en) 2004-12-21 2013-11-20 Nektar Therapeutics Stabilized polymeric thiol reagents
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
AU2006269382B2 (en) 2005-07-08 2014-01-16 Biogen Idec Ma Inc. Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
TW200817369A (en) * 2006-05-22 2008-04-16 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
US20100222546A1 (en) * 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
WO2009009712A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
WO2009009716A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
AU2009255994B2 (en) * 2008-06-05 2014-07-17 Bristol-Myers Squibb Company Use of pegylated Type III Interferons for the treatment of hepatitis C
UA104146C2 (ru) * 2008-07-31 2014-01-10 Фармаиссеншиа Корп. ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
JPWO2010140350A1 (ja) 2009-06-02 2012-11-15 パナソニック株式会社 ダウンミックス装置、符号化装置、及びこれらの方法
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
US11759500B2 (en) * 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
ES2824028T3 (es) 2014-08-19 2021-05-11 Biogen Ma Inc Método de PEGilación
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
RS65015B1 (sr) 2014-11-06 2024-01-31 Pharmaessentia Corp Režim doziranja pegiliranog interferona
ES2831079T3 (es) * 2017-06-28 2021-06-07 Construction Research & Technology Gmbh Dispersante para partículas inorgánicas
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
WO2020028715A1 (en) 2018-08-01 2020-02-06 Russell Alan J Amino-reactive positively charged atrp initiators that maintain their positive charge during synthesis of biomacro-initiators
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU3423293A (en) 1991-12-19 1993-07-19 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
AU697440B2 (en) 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
NZ322686A (en) * 1995-10-19 2000-01-28 Univ Washington Discrete-length polyethene glycols
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
EP0921817B1 (en) 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
CN1268980A (zh) 1997-03-05 2000-10-04 华盛顿州大学 用于鉴定选择性抑制丙型肝炎病毒复制的试剂的新筛选方法
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ES2222689T3 (es) 1998-03-12 2005-02-01 Nektar Therapeutics Al, Corporation Derivados del polietilenglicol con grupos reactivos proximales.
EE05214B1 (et) 1998-04-28 2009-10-15 Applied Research Systems Ars Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
PL206536B1 (pl) 1998-10-16 2010-08-31 Biogen Idec Inc Kompozycja, kompozycja farmaceutyczna glikozylowanego interferonu-beta-1a, zastosowanie kompozycji glikozylowanego interferonu-beta-1a, sposób in vitro przedłużania aktywności glikozylowanego interferonu-beta-1a
AU1249001A (en) * 1999-06-11 2001-01-31 Nektar Therapeutics Al, Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
JP2003527090A (ja) 1999-08-27 2003-09-16 マキシゲン・エイピーエス 新規なインターフェロンベータ様分子
ATE317868T1 (de) 1999-12-22 2006-03-15 Nektar Therapeutics Al Corp Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2002026265A2 (en) * 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
MXPA03006805A (es) * 2001-02-01 2003-11-13 Biogen Inc Conjugados de polimero de neublastina y metodos de uso de los mismos.
RU2003128955A (ru) 2001-02-27 2005-04-10 Максиген Апс (Dk) Новые интерферон бета-подобные молекулы
US7009033B2 (en) 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
DK2939696T3 (en) * 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
KR20050044858A (ko) * 2001-11-20 2005-05-13 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
KR100488351B1 (ko) 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
CA2952488C (en) * 2002-01-18 2019-05-07 Biogen Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compounds
KR20050093856A (ko) 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체 알카날
CA2511814C (en) 2002-12-26 2015-02-17 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Also Published As

Publication number Publication date
HUE028163T2 (en) 2016-11-28
US8524660B2 (en) 2013-09-03
EA009783B1 (ru) 2008-04-28
SI3025726T1 (sl) 2020-03-31
PL372728A1 (en) 2005-08-08
EE200400105A (et) 2004-12-15
WO2003061577A8 (en) 2008-11-20
EP1476181A4 (en) 2008-11-19
MEP35608A (en) 2011-02-10
NO2017013I2 (no) 2018-08-20
CN101700401B (zh) 2013-08-14
JP5275125B2 (ja) 2013-08-28
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
ES2566797T3 (es) 2016-04-15
US8017733B2 (en) 2011-09-13
CA2753899A1 (en) 2003-07-31
CA2952488C (en) 2019-05-07
EP3669887A1 (en) 2020-06-24
WO2003061577A3 (en) 2003-10-02
CY2016027I2 (el) 2017-06-28
EE05509B1 (et) 2012-02-15
DK1476181T3 (en) 2016-05-23
HK1072721A1 (zh) 2005-09-09
NZ534708A (en) 2007-05-31
RS63504A (en) 2007-02-05
PT3025726T (pt) 2020-01-09
CA2952488A1 (en) 2003-07-31
MXPA04006855A (es) 2005-04-19
BRPI0306993B8 (pt) 2021-05-25
CA2473526C (en) 2013-10-22
WO2003061577A2 (en) 2003-07-31
NO20043422L (no) 2004-10-11
LU93162I2 (fr) 2016-10-03
EP3025726B1 (en) 2019-11-20
CY1122841T1 (el) 2021-10-29
CZ2004877A3 (cs) 2004-12-15
NO2017013I1 (no) 2017-04-10
IL163006A (en) 2011-01-31
EA200400962A1 (ru) 2005-06-30
BG108839A (bg) 2005-04-30
BRPI0306993B1 (pt) 2020-03-10
US20120014916A1 (en) 2012-01-19
ES2774801T3 (es) 2020-07-22
CN101700401A (zh) 2010-05-05
CA2840490A1 (en) 2003-07-31
PL213322B1 (pl) 2013-02-28
BR0306993A (pt) 2005-09-06
JP2016014022A (ja) 2016-01-28
CA2840490C (en) 2017-02-28
JP2013136756A (ja) 2013-07-11
CY2016027I1 (el) 2017-06-28
DK3025726T3 (da) 2019-12-09
EP3025726A1 (en) 2016-06-01
JP2005526151A (ja) 2005-09-02
PL397261A1 (pl) 2012-03-26
GEP20064024B (en) 2007-01-10
EA011829B1 (ru) 2009-06-30
NL300826I2 (US20030051240A1-20030313-M00001.png) 2017-03-16
EA200701386A1 (ru) 2007-10-26
CA2753899C (en) 2014-03-25
KR20040081463A (ko) 2004-09-21
CN1630530A (zh) 2005-06-22
KR100964411B1 (ko) 2010-06-15
ME00239B (me) 2011-05-10
CA2473526A1 (en) 2003-07-31
HK1143553A1 (en) 2011-01-07
EP1476181A2 (en) 2004-11-17
HUP0500457A2 (hu) 2005-08-29
JP6030717B2 (ja) 2016-11-24
HK1224185A1 (zh) 2017-08-18
ZA200406555B (en) 2005-11-30
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
NO339857B1 (no) 2017-02-06
HUS1600035I1 (hu) 2016-10-28
JP2009235409A (ja) 2009-10-15
SK3102004A3 (sk) 2005-01-03
JP2012255156A (ja) 2012-12-27
NO20151082A1 (no) 2015-08-26
BE2016C040I2 (US20030051240A1-20030313-M00001.png) 2022-05-17
UA82184C2 (uk) 2008-03-25
NO344612B1 (no) 2020-02-10
US20050107277A1 (en) 2005-05-19
EP1476181B1 (en) 2016-03-23
BG66525B1 (bg) 2016-04-28
HUP0500457A3 (en) 2012-09-28
AU2003210564B2 (en) 2008-10-23
GEP20074024B (en) 2007-01-10
HUE047557T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
IS2989B (is) Pólýalkýlenfjölliðusambönd og gagn af þeim
IS7789A (is) Vatnsleysanlegir fjölliðualkanalar
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DE60330207D1 (de) le
DK2418220T3 (da) Interferon-alpha-antistoffer og anvendelser deraf
DE602004019245D1 (de) Polyethylenfolien
DE602004018654D1 (de) Se
DE60318511D1 (de) Gleitelement
DE60316445D1 (de) Funktionalisiertes polymer und verbesserte vulkanisate daraus
DE60325447D1 (de) Gleitelement
DE60308579D1 (de) Gleitelement
IS7783A (is) Flóð og fjöru-ker
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
IS8145A (is) Bý bíóísósterur af aktínóníni
DE602004027813D1 (de) Blockcopolymerzusammensetzung
DE60309482D1 (de) Polyethylenglykol-aldehydderivate
DK1601673T3 (da) Kondenserede heterocykler og anvendelser af disse
DE60230349D1 (de) Verbesserte Polymerzusammensetzung
DE602004000485D1 (de) Nachverbrennungsvorrichtung
ITBO20020304A1 (it) Nuovi condotti in materiale polimerico
DE60237110D1 (de) E/drain-serien-widerstand
ATA16232003A (de) Sortierer
DE502004002647D1 (de) Polymernetzwerke
DK1680134T3 (da) Sammensætninger og anvendelser deraf